$CERS stock has now risen 41% today, according to our price data from Polygon. There has been approximately $37,461,750 of trading volume.
It has been the 197th most-searched ticker on Quiver Quantitative over the last day, out of 12,339 total tickers searched.
Here is what we see in our data on $CERS (you can track the company live on Quiver's $CERS stock page):
$CERS Insider Trading Activity
$CERS insiders have traded $CERS stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $CERS stock by insiders over the last 6 months:
- WILLIAM MARINER GREENMAN (President and CEO) has made 0 purchases and 2 sales selling 525,944 shares for an estimated $898,826.
- RICHARD J BENJAMIN (Chief Medical Officer) has made 0 purchases and 4 sales selling 227,634 shares for an estimated $419,541.
- KEVIN DENNIS GREEN (Chief Financial Officer) has made 0 purchases and 3 sales selling 210,565 shares for an estimated $381,012.
- VIVEK K JAYARAMAN (Chief Operating Officer) has made 0 purchases and 2 sales selling 199,294 shares for an estimated $342,144.
- CHRYSTAL JENSEN (Chief Legal Officer) has made 0 purchases and 2 sales selling 85,845 shares for an estimated $155,359.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$CERS Hedge Fund Activity
We have seen 74 institutional investors add shares of $CERS stock to their portfolio, and 69 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. added 4,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,240,000
- MILLENNIUM MANAGEMENT LLC removed 2,502,368 shares (-72.1%) from their portfolio in Q4 2025, for an estimated $5,154,878
- AMOVA ASSET MANAGEMENT AMERICAS, INC. removed 975,218 shares (-17.2%) from their portfolio in Q4 2025, for an estimated $2,008,949
- BLACKROCK, INC. added 938,737 shares (+4.5%) to their portfolio in Q4 2025, for an estimated $1,933,798
- UBS GROUP AG added 793,244 shares (+227.1%) to their portfolio in Q4 2025, for an estimated $1,634,082
- TWO SIGMA INVESTMENTS, LP added 712,678 shares (+62.3%) to their portfolio in Q4 2025, for an estimated $1,468,116
- ARK INVESTMENT MANAGEMENT LLC removed 649,984 shares (-3.4%) from their portfolio in Q4 2025, for an estimated $1,338,967
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$CERS Revenue
$CERS had revenues of $59.9M in Q1 2026. This is an increase of 22.6% from the same period in the prior year.
You can track CERS financials on Quiver Quantitative's CERS stock page.
$CERS Government Contracts
We have seen $750,843 of award payments to $CERS over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- 25-007944 INTERCEPT PLATELET PROCESSING SETS: $115,699
- INTERCEPT PLATELET PROCESSING KITS: $77,888
- INTERCEPT BLOOD SYSTEM FOR PLATELETS AND PLASMA PATHOGEN REDUCTION SYSTEM AT ARMED SERVICES BLOOD BANK.: $73,176
- INTERCEPT PLATELET PROCESSING SET AND SERVICE MAINTENANCE: $64,626
- INTERCEPT PLATELET SET PN INT2140B: $44,528
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
$CERS Analyst Ratings
Wall Street analysts have issued reports on $CERS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 05/01/2026
To track analyst ratings and price targets for $CERS, check out Quiver Quantitative's $CERS forecast page.
You can track data on $CERS on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
